{
    "nctId": "NCT00574366",
    "briefTitle": "Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase I/II Trial of an Oral MTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination With an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva\u2122) In Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "To determine the maximum tolerated dose (MTD) of RAD001 given in combination with erlotinib (Phase I)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n* Evaluable metastatic disease (no need for measurable disease)\n* Must have had anthracycline therapy in the adjuvant setting or failed anthracycline treatment in the metastatic setting\n\n  * Total cumulative dose of lifetime exposure of doxorubicin not greater than 360 mg/m\\^2 or epirubicin not greater than 640 mg/m\\^2\n* Must have failed previous taxane (paclitaxel or docetaxel) therapy, defined as:\n\n  * Taxane use in the adjuvant setting with metastatic relapse within 12 months of therapy\n  * Progression on taxane therapy in the metastatic setting\n  * Discontinuation of taxane therapy in the metastatic setting secondary to lack of resolution of \u2265 grade 2 toxicity\n* No symptomatic brain metastases\n\n  * Patients with a history of brain metastases are eligible provided they are clinically stable and not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers\n  * Patients with asymptomatic brain metastasis are eligible provided they are not on prophylactic anticonvulsants that are CYP3A4 modifiers\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* SGOT and SGPT \u2264 2.5 times ULN\n* Albumin \\> 30 g/L\n* Creatinine \u2264 1.5 upper limit of normal\n* INR normal provided the patient is not on warfarin therapy\n* Not pregnant or nursing\n* Negative pregnancy test for premenopausal patients\n* Fertile patients must use effective barrier method contraception during and for 3 months after completion of study treatment\n* Patients must be disease-free of prior invasive cancers for \\> 5 years with the exception of basal cell or squamous cell cancer of the skin or cervical carcinoma in situ\n\nExclusion criteria\n\n* Serious or non-healing active wound, ulcer, or bone fracture\n* Known human immunodeficiency virus positivity\n* Uncontrolled intercurrent illness including, but not limited to, any of the following\n\n  * Ongoing or active infection requiring parenteral antibiotics\n  * Impairment of lung function (COPD, lung conditions requiring oxygen therapy)\n  * Symptomatic congestive heart failure (New York Heart Association class III or IV heart disease)\n  * Unstable angina pectoris or myocardial infarction within the past 6 months\n  * Uncontrolled hypertension (i.e., systolic blood pressure \\> 180 mm Hg or diastolic blood pressure \\> 100 mm Hg, found on two consecutive measurements separated by a 1-week period despite adequate medical support)\n  * Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment)\n  * Uncontrolled diabetes\n  * Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary\n\nPRIOR CONCURRENT THERAPY:\n\nInclusion criteria\n\n* See Disease Characteristics\n* Prior trastuzumab (Herceptin\u00ae) in the first-line treatment of metastatic breast cancer is required for patients who have HER2/neu overexpressing tumors\n* More than 6 months since prior cardiac angioplasty or stenting\n* Use of endocrine therapy (i.e., aromatase inhibitors, fulvestrant, tamoxifen or ovarian ablation) in the first-line treatment of metastatic breast cancer is required for patients who have estrogen receptor and or progesterone receptor expressing tumors\n\n  * Concurrent endocrine therapy is not allowed\n* Patients may receive concurrent radiotherapy to painful bone metastases or areas of impending bone fracture as long as radiotherapy is initiated prior to study entry\n\n  * Patients who have received prior radiotherapy must have recovered from toxicity induced by this treatment\n* More than 3 weeks since prior chemotherapy, biological or hormonal therapy while on protocol therapy.\n* No other concurrent antineoplastic or antitumor agents, including chemotherapy, radiotherapy, immunotherapy, or hormonal anticancer therapy\n\nExclusion criteria\n\n* More than 3 prior chemotherapy treatments in the metastatic setting\n\n  * This restriction does not include endocrine therapies or single agent biologic therapies (i.e., trastuzumab \\[Herceptin\u00ae\\])\n* Use of steroids or immunosuppressants\n* Use of CYP3A4 modifiers\n* Concurrent therapy with trastuzumab (Herceptin\u00ae)\n* Use of growth support factors (e.g., filgrastim \\[G-CSF\\], sargramostim \\[GM-CSF\\], recombinant erythropoietin) during the phase I portion of the study\n* Other concurrent investigational agents",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}